NCT06980428View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

December 4, 2026

Study Completion Date

December 4, 2026

Conditions
Healthy Participants
Interventions
DRUG

AZD4954

AZD4954 will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

Trial Locations (5)

21225

RECRUITING

Research Site, Brooklyn

32216

NOT_YET_RECRUITING

Research Site, Jacksonville

34452

NOT_YET_RECRUITING

Research Site, Inverness

78229

NOT_YET_RECRUITING

Research Site, San Antonio

91206

RECRUITING

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY